Clinical OMICs - Issue 3 - (Page 20)
Clinical OMICs INNOVATOR
Promoting Wellness & Demystifying Disease:
The 100K Project
Leroy Hood, M.D., Ph.D., and Nathan D. Price, Ph.D.
W
e believe that a longitudinal, Framingham-like study
of 100,000 well individuals
(hereafter termed the 100K project)
and their dynamical data clouds could
transform medicine by
1) providing scientifically validated
metrics for wellness,
2) allowing one to study the earliest
origins of disease in an individual
and 3) allow one to follow the entire
progression of a disease from its
beginning to end.
This proposal would allow us to
study the initiation and progression
of all common diseases and, from
that, learning how to predict and prevent these diseases would revolutionize healthcare.
Complexity, Disease,
and Systems Medicine
Contemporary medicine is challenged
by the incredible complexity of physiology and disease. Each individual
has unique genetic and environmental contexts. Clearly the traditional
20
Clinical OMICs May 15, 2014
reductionist approaches to disease
are insufficient to effectively deconvolute this complexity. Over the last
10 years systems approaches have
increasingly been employed, leading
to a new discipline designated systems medicine, which has two striking features.
First, each patient will be surrounded by a virtual cloud of billions of data points, and we will have
the analytical tools to reduce this
enormous dimensionality to simple
hypotheses of how to optimize wellness and minimize disease for each
individual. Second, the data can be
integrated and modeled to determine
the health and disease-associated
states of the "network of networks"
operating in each individual. These
interconnected networks manage
diverse types of biological information that operate at the chromosomal,
molecular, cellular, organ and even
individual levels.
In disease, these networks become
perturbed and this alters the information they manage and the func-
tions they carry out. Delineating this
altered and disease-perturbed information provides insights into disease
mechanisms, diagnostic markers, and
drug target candidates.
Systems medicine has reached
a tipping point and its emerging
technologies and systems-driven
strategies are already beginning to
alter the practice of medical discovery and of healthcare. Many strategies are helping to drive this future,
such as using the complete genome
sequencing of families to more rapidly identify disease genes, studying
disease dynamics in model organisms to provide fundamental insights
into disease mechanisms, pioneering systems approaches to blood
diagnostics to create powerful biomarker panels that can inform medical decisions, stratifying diseases
and patients into distinct subgroups
for more personalized treatments,
and using computational analyses
of disease-perturbed networks to
identify new classes of drug target
candidates.
www.clinicalomics.com
http://www.clinicalomics.com
Table of Contents for the Digital Edition of Clinical OMICs - Issue 3
Contents
Clinical OMICs - Issue 3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com